



Aurobindo Pharma receives final approval for Benazepril Hydrochloride Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Benazepril Hydrochloride Tablets, 10, 20 and 40 mg

Benazepril HCl Tablets are the generic equivalent of Novartis Pharmaceuticals' Lotensin® Tablets, which are indicated for the treatment of hypertension.

This is Aurobindo's 69th ANDA approval from the USFDA.

Since April 2008, the company has also received the final approval for its anti-infective product Penicillin V Potassium Tablets USP 250 mg and 500 mg and tentative approval for its anti-AIDS product Emtricitabine Capsules 200mg from the USFDA.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations

Aurobindo Pharma Limited

Reg Off: Plot No. 2, Maitrivihar, Ameerpeth, Hyderabad

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com